VHL is one of those diseases that you learn about in medical school but rarely see in practice, if ever. The NIH specializes in these “zebras.” ...

Von Hippel-Lindau (VHL) syndrome is a rare, inherited disease that causes the growth of cysts and tumors in various parts of the body. Learn more about VHL syndrome.

Constitutive activation of the HIF transcription factor is responsible for the hypervascularization that occurs in VHL-disease–associated renal cell carcinoma. 1,7,8 Accordingly, VEGF-targeted ...

And this is important for VHL, but it’s also important for other cancer syndromes, too. (They can learn) what they can expect throughout their life dealing with this (condition) and it just is a way ...

Mutations in VHL, which encodes von Hippel–Lindau tumor suppressor (VHL), are associated with divergent diseases. We describe a patient with marked erythrocytosis and prominent mitochondrial ...

Understanding the VHL Tumor Suppressor Complex. During the 1990s, several labs in the United States and United Kingdom investigated the von Hippel-Lindau tumor suppressor (pVHL). Jennifer Fisher ...

Hemangioblastomas often grow repeatedly in people with VHL. They are the cause of death for 82% of that group. Symptoms of a Hemangioblastoma. Large tumors put pressure on your brain and spine.

Among patients with other VHL-associated non-RCC tumors, results showed an ORR of 63% (95% CI, 41-81) in 24 patients with measurable CNS hemangioblastomas and an ORR of 83% (95% CI, 52-98) in 12 ...

According to rarediease.org, only 10,000 cases have been documented in the United states and according to UAB, the chance of a VHL holder being de novo is 20%.(De novo meaning the VHL holder did ...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics in 2019 ...